Article citationsMore>>

W. H. Sharfman, D. P. Lawrence, K. T. Flaherty, R. K. Amaravadi, K. B. Kim, R. Dummer, S. Gobbi, I. Puzanov, J. A. Sosman, K. Dohoney, L. P. Lam, S. Kakar, Z. Tang, O. Krieter and M. B. Atkins, “Results from the First-in-Human (FIH) Phase I Study of the Oral RAF inhibitor RAF265 Administered Daily to Patients with Advanced Cutaneous Melanoma,” Journal of Clinical Oncology, Vol. 29, 2011.

has been cited by the following article:

• TITLE: Current Trends and Future Directions in Clinical Trials for Malignant Melanoma Treatment Using Anti-Angiogenic Strategies

  AUTHORS: Daemon Dewing, Rowan Pritchard Jones

  KEYWORDS: Angiogenesis; Malignant Melanoma; Drug Trials; Vemurafinib; BRAF Mutation

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.4, August 9, 2012

  ABSTRACT: Melanoma is the most lethal skin cancer with a high propensity to metastasis and conventionally is poorly responsive to non-surgical treatments including chemotherapy and radiotherapy. Considerable advances have been made recently targeting BRAF mutations and immune regulation and, for the first time, credible options exist for patients with metastatic disease. Angiogenesis, the growth of new blood vessels, is an absolute prerequisite for tumour growth beyond a few millimetres in size. Melanoma neovascularisation is correlated with poor prognosis, reduced overall survival, ulceration and increased rate of relapse. Melanoma cells secrete several proangiogenic cytokines including Vascular Endothelial Growth Factor VEGF-A and raised levels of expression are associated with the switch from indolent radial, to invasive vertical and then metastatic growth phases. Understanding the processes underlying angiogenesis and how it relates to tumour growth broadly and to melanoma specifically is instrumental in the current drive to develop new treatments that target a range of tumour cell receptors and intracellular processes from receptor antagonism to monoclonal antibodies aimed at the disruption of the process of tumour angiogenesis. We discuss recent and current trials for metastatic melanoma therapy, and discuss potential directions of future treatment scheduling considering different treatment scheduling approaches beyond the parameters of standard drug trials.